Anthrax Vaccines
Emergent BioSolutions Remains Committed to Development of Enhanced Anthrax Countermeasures
Published in Medical Letter on the CDC and FDA, March 11th, 2007
Emergent BioSolutions Inc. (NYSE: EBS) announced that it has been informed by the National Institute of Allergy and Infectious Diseases (NIAID) that NIAID has cancelled its solicitation for bids that it sought under a request for proposals, RFP NIH-NIAID-DMID-07-05 "Development of a Third Generation Anthrax Vaccine," due to "programmatic considerations." The company was one of the respondents to this RFP, which NIAID issued in June 2006.
"Emergent BioSolutions remains committed to developing biodefense countermeasures, including anthrax vaccines and immune globulins," said Fuad El-Hibri, chairman and chief executive officer. "This cancellation from NIAID does not...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Addiction Medicine
Catalyst Pharmaceutical Partners, Inc. Strengthens Scientific Advisory Board With Appointment of Richard A. Rawson, Ph.D. - Adverse Drug Reactions
New Version of Devices to Treat Clogged Neck Arteries Approved by U.S. Food and Drug Administration - Analgesics
Elite Pharmaceuticals Provides Positive Clinical Update - Anthrax
FDA Grants Fast Track Designation to Emergent BioSolutions' BioThrax for Post-Exposure Prophylaxis against Anthrax Infection - Antisense Technology
Genta Incorporated Announces Fourth Quarter and Year End 2006 Financial Results and Corporate Highlights - Aortic Aneurysms
W. L. Gore & Associates Enrolls First Patient in Study of 45 mm GORE TAG Thoracic Endoprosthesis - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
